Marker and an assay for detection and monitoring of human immunodeficiency virus latency and activation

• US 5,576,176 A
• Filed: 03/03/1994
• Issued: 11/19/1996
• Est. Priority Date: 03/03/1994
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Romeo, Joseph, Busch, Michael P., Peterlin, Boris M., Adams, Melanie
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): MYERS, CARLA J
• Application Number:
  US08/206,384
• Time in Patent Office: 992 Days
• Field of Search: 435/5, 435/91.2, 435/91.21, 435/91.51, 536/24.32, 536/24.33, 536/23.1, 536/24.1, 935/8, 935/17, 935/18, 935/77, 935/78
• US Class Current: 435/5
• CPC Class Codes: C12Q 1/703 Viruses associated with AIDS
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

A marker and method for detection and monitoring of HIV latency and activation and an assay for detection of the marker. The assay sensitively detects HIV transcription and monitors HIV transcriptional activity by detecting the presence of short and long transcripts, quantifying both and determining the ratio of short to long transcripts. Short transcripts are abundant and a low ratio correlates with a latent-type transcriptional activity of HIV whereas the appearance of long transcripts signifies increased efficiency of transcriptional activity of HIV and the transition from latency to activation. The size difference between the TAR fragments appearing predominantly in latency and the full length transcripts appearing predominantly during the HIV activation is detected by RT-PCR assay that utilizes novel primers and probes. The results are expressed as a ratio of short to long transcripts. The obtained ratio is a sensitive tool in detection of HIV infection, the analysis of load of latent and active virus and monitoring the transition from the latent to active state of HIV replication.

Claims

1. A method for assessment of HIV transcriptional activity and disease progression wherein nonprocessive transcription indicates viral latency and processive transcription indicates active viral gene expression, wherein the method comprises determining a ratio of total RNA transcripts to processive RNA transcripts in infected cells of HIV positive subjects, and correlating a change in said ratio with disease progression wherein total RNA transcripts plus long transcripts and wherein short transcripts consist of SEQ ID NO:

1 and long transcripts comprise SEQ ID NO;

1 as a leader sequence of the full length viral mRNA wherein the level of said ratio indicates nonprocessive or processive transcription and the change in said ratio indicates a transition from latency to activation and correlates with disease progression.

2. The method of claim 1 wherein said determined ratio of total RNA transcripts to processive RNA transcripts in infected cells of HIV positive subjects is indicative of the relative amounts of nonprocessive and processive transcripts.

3. The method of claim 2 wherein the processive transcripts contain as a leader sequence the full sequence of the nonprocessive transcripts and detection of the leader sequence is equivalent to detecting total viral transcripts.

4. The method of claim 3 further comprising steps:

(a) detecting separately a level of total viral transcripts and a level of processive viral transcripts;

(b) determining the ratio of total viral transcripts and processive viral transcripts of step (a); and

(c) assessing the degree of processivity using the ratio of step (b);

(d) detecting a change of the ratio of total transcripts to processive transcripts; and

(e) correlating the degree of processivity of step (c) and the change of the ratio of step (d) with the degree of HIV latency, activation and disease progression.

8. The method of claim 4 wherein a detection of a high ratio of total transcripts to processive transcripts calculated in step (b) is correlated with and is indicative of nonprocessive HIV transcriptional activity.

9. The method of claim 8 wherein a detection of a nonprocessive HIV transcriptional activity indicates viral latency and correlates with an asymptomatic state of the HIV infection.

10. The method of claim 4 wherein a detection of a low ratio of total transcripts to processive transcripts calculated in step (b) is correlated with and is indicative of processive HIV transcriptional activity.

11. The method of claim 10 wherein a detection of a processive HIV transcriptional activity indicates viral activation and correlates with a symptomatic state of HIV infection.

12. The method of claim 4 wherein the change in the ratio is indicative of a transition from latent to active HIV replication or from active to latent HIV replication and is correlated with disease progression.

5. A method for assessment of HIV transcriptional activity and disease progression wherein nonprocessive transcription indicates viral latency and processive transcription indicates active viral gene expression, wherein the methods comprises determining a ratio of nonprocessive RNA transcripts to processive RNA transcripts in infected cells of HIV positive subjects, and correlating a change in said ratio with disease progression wherein short transcripts consist of SEQ ID NO:

1 and long transcripts comprise SEQ ID NO;

1 as a leader sequence of the full length viral mRNA wherein the change in said ratio indicates a transition from latency to activation and correlates with disease progression.

6. A method for assessment of HIV transcriptional activity and disease progression comprising determining the ratio of short nonprocessive RNA transcripts to long processive RNA transcripts wherein short transcripts consist of SEQ ID NO:

1 and long transcripts comprise SEQ ID NO;

1 as a leader sequence of the full length viral mRNA wherein nonprocessive transcription indicates viral latency and processive transcription indicates active viral gene expression and changes in the relative amounts of processive and nonprocessive transcripts are correlated with disease progression wherein a change in said ratio indicates a transition from latency to activation and correlates with disease progression.

7. An assay for monitoring HIV transcriptional activity and disease progression comprising determining relative levels of nonprocessive transcription and processive transcription, wherein short nonprocessive transcripts consist of SEQ ID NO:

1 and long processive transcripts comprise SEQ ID NO;

1 as a leader sequence of the full length vital mRNA, calculating these levels as a ratio, and correlating a change in said ratio with disease progression wherein a change in said ratio is correlated with a transition from latency to activation and correlates with disease progress.

13. The assay of claim 7 further comprising the steps of:

(a) obtaining HIV infected cells;

(b) extracting RNA from the cells of step (a) or fixing the cells of step (a) for in situ detection of RNA;

(c) preparing cDNA from RNA extracted from the cells obtained in step (b);

(d) amplifying the cDNA with primer set comprising sequences (SEQ ID NO;

     2); and

(SEQ ID NO;

     3);

to generate amplification products from a leader sequence of all viral transcripts;

and with a primer set comprising sequences (SEQ ID NO;

     2); and

(SEQ ID NO;

     4);

to generate amplification from the processive transcripts;

(e) hybridizing the amplified product of step (d) with a labeled probe having a sequence (SEQ ID NO;

     5);

(f) detecting the product formed by hybridization of the probe of step (e) with the amplified cDNA; and

(g) quantitating the ratio of amplification products obtained from total transcripts and processive transcripts; and

(h) correlating the high or low ratio with HIV transcriptional activity.

14. The assay of claim 13 wherein a decreased ratio of total to processive transcripts is correlated with a progression of a HIV disease from latency to activation.

15. The assay of claim 14 wherein the product formed in the step (e) of claim 13 is detected by slide-based or flow cytometric detection systems.

16. The assay of claim 15 wherein the product of step (e) of claim 13 is detected by gel electrophoresis.